Cardionovum

Be up
to date.

Latest press release

Dr. Lichtenberg discusses about Aperto® drug-coated balloon technology and its promising results in dialysis access patients

Prof. Michael Lichtenberg (Arnsberg, Germany) speaks to Vascular News at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2022 annual meeting in Barcelona (Spain) about the importance on new endovascular strategies, such as Drug-Coated Balloons (DCBs), to improve patency rates in patients with consecutive neointimal hyperplasia in haemodialysis access.

 

In this interview, a particular focus is put on the promising results of APERTO® OTW, our high-pressure paclitaxel releasing DCB, considered as “one of the very promising new technologies” for treating restenosis in dialysis access patients

Learn more >>

Late-Breaking Xlimit RCT data presented at CSC Congress demonstrate an equivalent performance of the Xlimus® DES in terms of OCT derived endpoints than the Synergy™ DES.

Bonn, Germany. November 16, 2022 – Data presented at Innovation session today at the CSC 2022 congress demonstrated an equivalent performance of the Xlimus® DES in terms of OCT derived endpoints than the Synergy™ DES, including Neointimal Volume and Neointimal Volume weighted by length at 6 months. Secondary endpoints, including other OCT parameters, such as in-stent Minimum Lumen Area (MLA) and percentage of strut coverage as well as clinical endpoints, showed no significant differences between the two groups in any of the evaluated parameters within the Xlimit RCT.

Learn more >>

Prof. Matteo Tozzi discusses about new data bolster safety and effectiveness of Safepax®

Prof. Matteo Tozzi (Varese, Italy) speaks to Vascular News at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2022 annual meeting in Barcelona (Spain) about his new study that analyzes the concentrations of paclitaxel in the bloodstream after the use of a Drug-Coated Balloons (DCBs) in AVFs.

Learn more >>

CARDIONOVUM® announces regulatory approval of APERTO® OTW in Mexico

We are proud to announce that we have received the authorization by the Secretaria de Salud and COFEPRIS to distribute APERTO® OTW in Mexico.

Learn more >>

Cardionovum® announces First Procedure in Hyper II International Clinical Trial.

CARDIONOVUM® today announced the enrollment of the first patient in the International Hyper II Clinical Study

Learn more >>

CARDIONOVUM® announces the first Signature RCT patient enrollment

On June 8th, in Sankt Gertrauden hospital in Berlin, Germany, the first Signature RCT patient has been enrolled

Learn more >>

Upcoming events

Currently there are no events.

Latest events

Cardionovum at EuroPCR 18, 19, 20 May 2021

Cardionovum invites you to participate in on demand interviwes:

  • XLIMIT Trial RCT, with Dr. Luca Testa from Italy.
    Goal: to assess angiographic and clinical performance of the Xlimus Biodegradable Polymer Sirolumus-eluting stent versus a gold standard like Synergy Biodegradable Polymer Everolimus Stent in patients treated with percutaneous coronary angioplasty.

  • Hyper Registry with Dr. Alfonso Ileasi from Italy.
    Goal: Asses the clinical results after a Hybrid Approach in diffuse CAD lesions longer tan 28mm combinig Restore DCB and New generation DES.

Date: May 18, 2021–May 21, 2021

Learn more >>

Cardionovum - Meeting & Symposium at LINC 2020

Cardionovum participates at LINC
Leipzig Interventional Course
You are welcome to visit us at booth no. 19 c

Date: Jan 28, 2020–Feb 01, 2020

Location: Leipzig, Germany

Learn more >>

Visit website >>

Cardionovum at EuroPCR

Cardionovum participates at EuroPCR 2019
You are welcome to visit us at booth no. M 7 (level 2)

Date: May 21, 2019–May 25, 2019

Location: Paris, France

Visit website >>

go top